Literature DB >> 19753144

Prevalence and significance of coagulation abnormalities in community-acquired pneumonia.

Eric B Milbrandt1, Michael C Reade, MinJae Lee, Stephanie L Shook, Derek C Angus, Lan Kong, Melinda Carter, Donald M Yealy, John A Kellum.   

Abstract

Coagulation abnormalities are common in severe pneumonia and sepsis, yet little is known about the presence of coagulopathy or its significance in patients with lesser illness severity. We examined coagulation abnormalities in 939 subjects hospitalized with community-acquired pneumonia (CAP) in 28 US hospitals, hypothesizing that abnormalities would increase with illness severity and poor outcomes. We measured plasma coagulation markers (D-dimer, plasminogen activator inhibitor [PAI], antithrombin, factor IX, and thrombin-antithrombin complex [TAT]) at the time of patient presentation to the emergency department and daily during the first wk of hospitalization. Day-1 clinical laboratory test results for international normalized ratio, activated partial thromboplastin time, and platelet count were recorded from the medical record. In our cohort, 32.5% of patients developed severe sepsis and 11.1% died by d 90. Day-1 coagulation abnormalities were common, especially for D-dimer (80.6%) and TAT (36.0%), and increased with illness severity and poor outcomes. However, abnormalities also occurred in those patients who never developed organ dysfunction and differences between groups were modest. The proportion of patients with abnormalities changed over time, yet the magnitude of change was small and not always in the direction of normality. Many patients remaining in the hospital continued to manifest coagulation abnormalities on d 7, especially for D-dimer (86.5%) and TAT (36.9%). In conclusion, coagulation abnormalities were common and persistent in CAP patients, even among the least ill. These findings underscore the complexity of the coagulation response to infection and may offer insights into coagulation-based therapeutics in clinical sepsis trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19753144      PMCID: PMC2743205          DOI: 10.2119/molmed.2009.00091

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  37 in total

1.  Coagulation abnormalities in acute lung injury and sepsis.

Authors:  E Abraham
Journal:  Am J Respir Cell Mol Biol       Date:  2000-04       Impact factor: 6.914

2.  Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.

Authors:  Anita W Rijneveld; Sebastiaan Weijer; Paul Bresser; Sandrine Florquin; George P Vlasuk; William E Rote; C Arnold Spek; Pieter H Reitsma; Jaring S van der Zee; Marcel Levi; Tom van der Poll
Journal:  Crit Care Med       Date:  2006-06       Impact factor: 7.598

3.  Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis.

Authors:  Sachin Yende; Gina D'Angelo; John A Kellum; Lisa Weissfeld; Jonathan Fine; Robert D Welch; Lan Kong; Melinda Carter; Derek C Angus
Journal:  Am J Respir Crit Care Med       Date:  2008-03-27       Impact factor: 21.405

4.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

5.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Authors:  Edward Abraham; Pierre-François Laterre; Rekha Garg; Howard Levy; Deepak Talwar; Benjamin L Trzaskoma; Bruno François; Jeffrey S Guy; Martina Brückmann; Alvaro Rea-Neto; Rolf Rossaint; Dominique Perrotin; Armin Sablotzki; Nancy Arkins; Barbara G Utterback; William L Macias
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

6.  Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

Authors:  Simon Nadel; Brahm Goldstein; Mark D Williams; Heidi Dalton; Mark Peters; William L Macias; Shamel A Abd-Allah; Howard Levy; Robinette Angle; Dazhe Wang; David P Sundin; Brett Giroir
Journal:  Lancet       Date:  2007-03-10       Impact factor: 79.321

7.  Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure.

Authors:  Jean-Francois Dhainaut; Andrew F Shorr; William L Macias; Marin J Kollef; Marcel Levi; Konrad Reinhart; David R Nelson
Journal:  Crit Care Med       Date:  2005-02       Impact factor: 7.598

8.  Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia.

Authors:  David T Huang; Lisa A Weissfeld; John A Kellum; Donald M Yealy; Lan Kong; Michael Martino; Derek C Angus
Journal:  Ann Emerg Med       Date:  2008-03-17       Impact factor: 5.721

Review 9.  The coagulation cascade in sepsis.

Authors:  Ling Wang; Julie A Bastarache; Lorraine B Ware
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study.

Authors:  John A Kellum; Lan Kong; Mitchell P Fink; Lisa A Weissfeld; Donald M Yealy; Michael R Pinsky; Jonathan Fine; Alexander Krichevsky; Russell L Delude; Derek C Angus
Journal:  Arch Intern Med       Date:  2007 Aug 13-27
View more
  47 in total

1.  Understanding the potential role of statins in pneumonia and sepsis.

Authors:  Sachin Yende; Eric B Milbrandt; John A Kellum; Lan Kong; Russell L Delude; Lisa A Weissfeld; Derek C Angus
Journal:  Crit Care Med       Date:  2011-08       Impact factor: 7.598

2.  Effects of Aging on Inflammation and Hemostasis through the Continuum of Critical Illness.

Authors:  Sachin S Kale; Sachin Yende
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

3.  Is Pneumonia a Risk Factor or a Risk Marker for Long-Term Mortality?

Authors:  Carlos G Grijalva
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

4.  D-dimer threshold increase with pretest probability unlikely for pulmonary embolism to decrease unnecessary computerized tomographic pulmonary angiography.

Authors:  J A Kline; M M Hogg; D M Courtney; C D Miller; A E Jones; H A Smithline
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

Review 5.  Fibrinogen Is at the Interface of Host Defense and Pathogen Virulence in Staphylococcus aureus Infection.

Authors:  Ya-Ping Ko; Matthew J Flick
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

Review 6.  The role of biomarkers in diagnosis of COVID-19 - A systematic review.

Authors:  Muhammed Kermali; Raveena Kaur Khalsa; Kiran Pillai; Zahra Ismail; Amer Harky
Journal:  Life Sci       Date:  2020-05-13       Impact factor: 5.037

7.  Risk factors for pulmonary embolism in patients preliminarily diagnosed with community-acquired pneumonia: a prospective cohort study.

Authors:  Yunfeng Zhang; Qixing Zhou; Ying Zou; Xiaolian Song; Shuanshuan Xie; Min Tan; Guoliang Zhang; Changhui Wang
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

8.  Upsurge of deep venous thrombosis in patients affected by COVID-19: Preliminary data and possible explanations.

Authors:  Enrico M Marone; Luigi F Rinaldi
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2020-04-17

9.  Is prolonged low-dose glucocorticoid treatment beneficial in community-acquired pneumonia?

Authors:  Marco Confalonieri; Djillali Annane; Caterina Antonaglia; Mario Santagiuliana; Ediva M Borriello; G Umberto Meduri
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

10.  Dynamic Changes in Coagulation Function in Patients With Pneumonia Under Admission and Non-admission Treatment.

Authors:  Jiasheng Xu; Yongmei Zhang; Yiran Li; Kaili Liao; Xiong Zeng; Xiande Zeng; Rui Meng; Weimin Zhou; Kai Wang; Yuanqi Gong; Fuzhou Hua; Jianjun Xu; Jiehua Qiu
Journal:  Front Med (Lausanne)       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.